Racially-based disparities in ca on the rise, not due to smoking

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

A new study found that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking related cancers, and that cancer mortality differences related to screening and treatment may still be increasing. The study is the first to analyze racial and ethnic differences between the two broad categories of disease.

A new study found that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking related cancers, and that cancer mortality differences related to screening and treatment may still be increasing. The study is the first to analyze racial and ethnic differences between the two broad categories of disease.

Despite decreases in overall cancer death rates across all racial and ethnic groups since the early 1990s, racial disparities in cancer mortality persist, according to the study results. African Americans had the highest risk of all major ethnic groups in the U.S. of being diagnosed with and dying of cancer (Cancer Epidemiol Biomarkers Prev 17:2908-2912, 2008).

Negative messages make minorities skip screening

Emphasizing the negative consequences of a lack of cancer screening can make minority patients avoid it, according to a study from the St. Louis University School of Public Health.

Robert Nicholson, PhD, and colleagues asked 300 African-American adults to read articles about colon cancer.

The researchers found that articles that relied on scare tactics actually discouraged an interest in screening, while articles about positive outcomes made people more open to screening (Cancer Epidemiol Biomarkers Prev 17:2946-2953, 2008).

Recent Videos
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content